These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 3940646

  • 1. Proliferative response of the Dunning R3327H experimental model of prostatic adenocarcinoma to conditions of androgen depletion and repletion.
    English HF, Kloszewski ED, Valentine EG, Santen RJ.
    Cancer Res; 1986 Feb; 46(2):839-44. PubMed ID: 3940646
    [Abstract] [Full Text] [Related]

  • 2. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat.
    Brändström A, Westin P, Bergh A, Cajander S, Damber JE.
    Cancer Res; 1994 Jul 01; 54(13):3594-601. PubMed ID: 8012987
    [Abstract] [Full Text] [Related]

  • 3. Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer.
    Smolev JK, Heston WD, Scott WW, Coffey DS.
    Cancer Treat Rep; 1977 Jul 01; 61(2):273-87. PubMed ID: 872132
    [Abstract] [Full Text] [Related]

  • 4. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
    Joseph IB, Nelson JB, Denmeade SR, Isaacs JT.
    Clin Cancer Res; 1997 Dec 01; 3(12 Pt 1):2507-11. PubMed ID: 9815654
    [Abstract] [Full Text] [Related]

  • 5. Unusual androgen sensitivity of the androgen-independent Dunning R-3327-G rat prostatic adenocarcinoma: androgen effect on tumor cell loss.
    Humphries JE, Isaacs JT.
    Cancer Res; 1982 Aug 01; 42(8):3148-56. PubMed ID: 7093958
    [Abstract] [Full Text] [Related]

  • 6. Rapid androgen cycling as treatment for patients with prostate cancer.
    Feltquate D, Nordquist L, Eicher C, Morris M, Smaletz O, Slovin S, Curley T, Wilton A, Fleisher M, Heller G, Scher HI.
    Clin Cancer Res; 2006 Dec 15; 12(24):7414-21. PubMed ID: 17189414
    [Abstract] [Full Text] [Related]

  • 7. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT.
    Clin Cancer Res; 2006 Jul 01; 12(13):4072-9. PubMed ID: 16818707
    [Abstract] [Full Text] [Related]

  • 8. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT.
    Cancer Res; 1999 May 15; 59(10):2395-401. PubMed ID: 10344749
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer.
    English HF, Heitjan DF, Lancaster S, Santen RJ.
    Cancer Res; 1991 Apr 01; 51(7):1760-5. PubMed ID: 2004359
    [Abstract] [Full Text] [Related]

  • 11. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model.
    Bonkhoff H, Remberger K.
    Prostate; 1996 Feb 01; 28(2):98-106. PubMed ID: 8604398
    [Abstract] [Full Text] [Related]

  • 12. Determination of the proliferative fraction of a transplantable, hormone-dependent, human prostatic carcinoma (PC-82) by monoclonal antibody Ki-67: potential application for hormone therapy monitoring.
    Gallee MP, van Steenbrugge GJ, ten Kate FJ, Schroeder FH, van der Kwast TH.
    J Natl Cancer Inst; 1987 Dec 01; 79(6):1333-40. PubMed ID: 3320449
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tumor progression in serial passages of the Dunning R3327-G rat prostatic adenocarcinoma: growth rate response to endocrine manipulation.
    Pollack A, Block NL, Stover BJ, Irvin GL.
    Cancer Res; 1985 Mar 01; 45(3):1052-7. PubMed ID: 3971360
    [Abstract] [Full Text] [Related]

  • 15. Influence of diethylstilbestrol, Leuprolelin (a luteinizing hormone-releasing hormone analog), Finasteride (a 5 alpha-reductase inhibitor), and castration on the lobar subdivisions of the rat prostate.
    Yamashita A, Hayashi N, Sugimura Y, Cunha GR, Kawamura J.
    Prostate; 1996 Jul 01; 29(1):1-14. PubMed ID: 8685049
    [Abstract] [Full Text] [Related]

  • 16. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma.
    Isaacs JT, Coffey DS.
    Cancer Res; 1981 Dec 01; 41(12 Pt 1):5070-5. PubMed ID: 7307008
    [Abstract] [Full Text] [Related]

  • 17. Quiescence in R3327-G rat prostate tumors after androgen ablation.
    Pollack A, Joon DL, Wu CS, Sikes C, Hasegawa M, Terry NH, White RA, Zagars GK, Meistrich ML.
    Cancer Res; 1997 Jun 15; 57(12):2493-500. PubMed ID: 9192831
    [Abstract] [Full Text] [Related]

  • 18. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.
    Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL.
    Clin Cancer Res; 2005 Jul 01; 11(13):4653-7. PubMed ID: 16000557
    [Abstract] [Full Text] [Related]

  • 19. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis.
    Aranha O, Grignon R, Fernandes N, McDonnell TJ, Wood DP, Sarkar FH.
    Int J Oncol; 2003 Apr 01; 22(4):787-94. PubMed ID: 12632069
    [Abstract] [Full Text] [Related]

  • 20. Androgen sensitivity of prostate epithelium is enhanced by postnatal androgen receptor inactivation.
    Simanainen U, McNamara K, Gao YR, Handelsman DJ.
    Am J Physiol Endocrinol Metab; 2009 Jun 01; 296(6):E1335-43. PubMed ID: 19366880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.